For the Inventor, By the Inventor

Enter assignee name

Hellerup, Denmark

Union Therapeutics A/s

USPTO Granted Patents = 22

% Expired Patents = 4.5

EPO Patents = 12

Forward Citations = 76

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Morten Otto Alexander Sommer (12 out of 13 patents)

Rasmus Vendler Toft-Kehler (9 out of 10 patents)

Daniel Jean Jacques Simon (7 out of 8 patents)

4. Jens Larsen (4 out of 8 patents)

5. Emilie Flora Aurore Delavenne (4 out of 5 patents)

6. Mark Andrews (3 out of 5 patents)

7. Allan Carsten Dahl (3 out of 3 patents)

8. Daniel Rodriguez Greve (3 out of 14 patents)

9. Anne Katrine Toft-Kehler (2 out of 2 patents)

10. Mads Jellingsoe (2 out of 2 patents)

11. Günter Ditzinger (2 out of 2 patents)

12. Philippe Andres (2 out of 2 patents)

13. Matthias Manne Knopp (2 out of 2 patents)

14. Johan Eriksson Bajtner (2 out of 2 patents)

15. Esben Paul Krogh Olsen (2 out of 2 patents)

22 patents: Sort by Forward Citations

1. 12409172 - Dosage regimen (2025-09-09),

2. 12084457 - Methods for the preparation of 1,3-benzodioxole heterocyclic compounds (2024-09-10),

3. 12036312 - Non-aqueous topical compositions comprising a halogenated salicylanilide (2024-07-16),

4. 11981681 - Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors (2024-05-14),

5. 11866445 - Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors (2024-01-09),

6. 11529361 - Halogenated salicylanilides for treatinginfections (2022-12-20),

7. 11384096 - Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors (2022-07-12),

8. 11370799 - Methods for the preparation of 1,3-benzodioxole heterocyclic compounds (2022-06-28),

9. 11365204 - Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors (2022-06-21),

10. 11331327 - Antibacterial use of halogenated salicylanilides (2022-05-17),

11. 11331289 - Antimicrobial composition (2022-05-17),

12. 11324761 - Antibacterial use of halogenated salicylanilides (2022-05-10),

13. 11324708 - Niclosamide formulations for treating disease (2022-05-10),

14. 11299497 - Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors (2022-04-12),

15. 11292799 - Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors (2022-04-05),

Company Overview

Union Therapeutics A/S is a biotechnology company based in Hellerup, Denmark, focused on developing innovative therapies for patients with unmet medical needs. The company specializes in the research and development of novel treatments, particularly in the areas of dermatology and respiratory diseases. Union Therapeutics leverages advanced scientific expertise and cutting-edge technology to create effective solutions, aiming to improve the quality of life for patients globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

22 Patents

#2 in Hellerup

#137 in Denmark

#28,807 in the World

Hellerup, Denmark

Union Therapeutics A/s

Forward Citations = 76

35 inventors:

Morten Otto Alexander Sommer (12 out of 13 patents)

Rasmus Vendler Toft-Kehler (9 out of 10 patents)

Daniel Jean Jacques Simon (7 out of 8 patents)

4. Jens Larsen (4 out of 8 patents)

5. Emilie Flora Aurore Delavenne (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Union Therapeutics A/s. Retrieved from https://idiyas.com/company/union-therapeutics-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…